Looking at this filing, I need to identify the key facts and build a complete, properly structured article about Kymera Therapeutics, Inc.'s 10-Q for the quarterly period ended June 30, 2026.

Kymera Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended June 30, 2026, disclosing its financial position and operational status as a clinical-stage biopharmaceutical company.

Key Highlights

  • Share count: As of July 31, 2026, Kymera Therapeutics had 83,150,618 shares of common stock, $0.0001 par value per share, outstanding.
  • Exchange listing: Common stock trades on The Nasdaq Global Market under the symbol KYMR.
  • Filer status: The company is classified as a large accelerated filer, and is not a smaller reporting company or emerging growth company.
  • Clinical stage: According to the filing, the company is clinical stage with product candidates in early clinical development, including programs targeting IRAK4, CDK2, STAT6, and IRF5.
  • Operating losses: The filing states the company "has incurred significant operating losses since our inception and anticipates that we will incur continued losses for the foreseeable future."
  • Capital needs: The company disclosed it "will need to raise substantial additional funding" to continue development and commercialization efforts.

Kymera Therapeutics: Clinical Pipeline and Disclosed Risk Factors

Kymera Therapeutics, Inc. (Nasdaq: KYMR), headquartered at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472, filed its quarterly report covering the period ended June 30, 2026. The company describes itself as a clinical-stage company pursuing a novel and unproven approach to drug discovery and development. The filing notes that this approach "makes it difficult to predict the time, cost of development and likelihood of successfully developing any products," according to the company's own disclosures.

The company identified several active development programs in its forward-looking disclosures, including programs targeting IRAK4, CDK2, STAT6, and IRF5. The filing references collaboration arrangements for the IRAK4 and CDK2 programs, and clinical studies for its STAT6 and IRF5 programs. Kymera also stated plans to submit investigational new drug applications to the U.S. Food and Drug Administration for current and future product candidates, and noted its reliance on third-party organizations to conduct preclinical studies and clinical trials.

Among the material risks the company disclosed, it stated that it relies, and expects to continue to rely, "on third parties to conduct our ongoing and planned preclinical studies and clinical trials." The filing also identified unstable global economic and geopolitical conditions as a potential source of adverse consequences for its business, financial condition, and stock price. All forward-looking statements in the quarterly report were made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the company's cautionary language as set forth in the filing.

What Was Disclosed

Kymera Therapeutics filed a Form 10-Q for the quarter ended June 30, 2026, reporting 83,150,618 shares outstanding as of July 31, 2026, its large accelerated filer classification, ongoing clinical-stage operations, continued operating losses, and a requirement for additional funding.